Gimv

Fredrick Goodwill Partners With Give Back Box and Fashion Influencer To Promote Sustainable Secondhand Shopping

Wednesday, July 1, 2020 - 1:05am

The Future of Fashion section highlights key solutions contributing to the creation of a conscientious future of fashion.

Key Points: 
  • The Future of Fashion section highlights key solutions contributing to the creation of a conscientious future of fashion.
  • Participants simply fill any box with donations and ship them using a prepaid label from givebackbox.com.
  • GIMV collaborated with fashion influencer, Priscilla Andalia of the Best Trends for Life blog, to spread awareness of the ways in which secondhand shopping supports a sustainable lifestyle.
  • The partnership promotes recycling, repurposing, and giving a second life to items that may otherwise end up in landfills.

JenaValve Technology Closes $50 Million Financing

Wednesday, February 5, 2020 - 11:00am

JenaValve Technology, Inc. , developer and manufacturer of the JenaValve Pericardial Transcatheter Aortic Valve Replacement (TAVR) System for the treatment of aortic valve disease, announces that it has raised $50 million in an equity financing led by Bain Capital Life Sciences .

Key Points: 
  • JenaValve Technology, Inc. , developer and manufacturer of the JenaValve Pericardial Transcatheter Aortic Valve Replacement (TAVR) System for the treatment of aortic valve disease, announces that it has raised $50 million in an equity financing led by Bain Capital Life Sciences .
  • Additional participants in the financing included existing investors Andera Partners, Gimv, Legend Capital, NeoMed Management, RMM, Valiance Life Sciences and VI Partners.
  • The Company also announces the appointment of Andrew Hack, MD, PhD, Managing Director of Bain Capital, to the JenaValve Board of Directors.
  • This financing supports our ongoing clinical program and plans to file for U.S. Humanitarian Device Exemption (HDE) approval in the second half of 2020.

ImCheck Raises $53 Million Series B to Advance Clinical Pipeline of Novel Gamma Delta T-Cell-Focused Antibodies for Cancer and Autoimmune Diseases

Wednesday, December 4, 2019 - 5:45am

Life Sciences Partners (LSP), Gimv, Idinvest Partners, Kurma Partners and Boehringer Ingelheim Venture Fund that contributed to the 2017 20 Million Series A round also participated for a significant portion of this raise.

Key Points: 
  • Life Sciences Partners (LSP), Gimv, Idinvest Partners, Kurma Partners and Boehringer Ingelheim Venture Fund that contributed to the 2017 20 Million Series A round also participated for a significant portion of this raise.
  • "We believe this investment represents a strong validation of our pipeline and its potential both in cancer and autoimmune diseases.
  • In addition, preclinical experiments with ImChecks antagonist antibodies have demonstrated potential as treatments for a wide range of autoimmune diseases.
  • For further information on ImCheck: http://www.imchecktherapeutics.com and @ImCheckThx
    For further information on the participating funds:

Mérieux Equity Partners Announced That Benoit Chastaing Has Joined the Firm as Senior Partner

Thursday, January 17, 2019 - 11:00am

Mrieux Equity Partners announced today that Benoit Chastaing has joined the firm as Senior Partner, to foster the firm's growth capital, MBO/LBO and majority investment activities relating to small and mi-cap companies within the healthcare and nutrition sectors.

Key Points: 
  • Mrieux Equity Partners announced today that Benoit Chastaing has joined the firm as Senior Partner, to foster the firm's growth capital, MBO/LBO and majority investment activities relating to small and mi-cap companies within the healthcare and nutrition sectors.
  • Benoit Chastaing brings to Mrieux Equity Partners a solid track-record in managing and financing fast growing companies within the sectors of interest of Mrieux Participations 3, the third generation vehicle recently launched with the support of several large family holdings and institutional investors.
  • Benoit was until recently an active member of the investment firm Gimv, as Partner in charge of growth capital investment in France from 2016 to 2018.
  • In this role, he led multiple majority deals such as Stiplastics Group and France Thermes and actively supported Almaviva, until its acquisition by Antin Investment Partners.